SARS-Cov-2

Moderna said Wednesday that it will submit a request to the FDA “in the coming weeks” seeking authorization of its COVID-19 vaccine for children aged younger than 6 years.

Severe COVID-19 was associated with ophthalmological manifestations in more than one-third of patients who presented to a single center with the disease, according to a study published in Retina.

Data from the CDC revealed an increase in SARS-CoV-2 levels among 165 wastewater surveillance sites in the United States.

In this video, Amesh A. Adalja, MD, a senior scholar in the Johns Hopkins Center for Health Security, describes his experiences during the first months of the COVID-19 pandemic in 2020.

Moderna announced that it is seeking an emergency use authorization from the FDA for an additional booster dose of its COVID-19 vaccine for all adults.

What started as an outbreak of viral pneumonia that infected dozens of people in a city in central China has grown into a pandemic that has killed nearly one million people in the United States alone.

Pfizer and BioNTech announced this week that they are seeking an emergency use authorization from the FDA for an additional booster dose of their COVID-19 vaccine for older adults.

The CDC’s wastewater surveillance tracker shows that 165 U.S. sites have experienced an increase in SARS-CoV-2 levels in the last 15 days.

The Pfizer-BioNTech COVID-19 vaccine reduced the risk for infection with the omicron variant of SARS-CoV-2 by 31% among children aged 5 to 11 years and 59% among adolescents aged 12 to 15 years, according to data published Friday in MMWR.

Disruptions related to the COVID-19 pandemic led to steep declines in cases of dengue in endemic regions, with more than 723,000 cases averted in 2020, researchers reported in Lancet Infectious Diseases.